Supplementary Table 1 from PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
Year: 2023
Type: supplementary-materials
Abstract: Supplementary Table 1 from PF00299804, an Irreversible Pan-ERBB Inhibitor, Is Effective in Lung Cancer Models with EGFR and ERBB2 Mutations that Are Resistant to Gefitinib
Authors: Jeffrey A. Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale, Eugene Lifshits, Andrea J. Gonzales, Takeshi Shimamura, Feng Zhao, Patrick W. Vincent, George N. Naumov, James E. Bradner, Irene W. Althaus, Leena Gandhi, Geoffrey I. Shapiro, James M. Nelson, John V. Heymach, Matthew Meyerson, Kwok-Kin Wong, Pasi A. Jänne
Language: English
Subfield: Pulmonary and Respiratory Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: gold
OpenAlex ID: W4361247548